ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
AC Immune says partner Roche to start second late-stage study of Alzheimer's disease drug crenezumab
March 01, 2017Roche's partner AC Immune said Tuesday that the former has decided to initiate a second Phase III study of the experimental Alzheimer's disease therapy crenezumab. AC Immune noted that the CREAD2 trial will enrol 750 patients with prodromal or mild Alzhei
Pharma Sources Insight January 2025
